Efficacy and safety of anti-manic agents in children and adults

Arif Khan, James Faucett, Graham J. Emslie, Walter A. Brown

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Pediatric trials in depression have led to major concerns about potential suicide inducing properties of antidepressants and doubts about their efficacy. Several trials of anti-manic agents in children were recently conducted and regulatory reviews of the data have become available. Methods: We acquired pediatric and adult anti-mania agent Medical and Statistical Reports from the U.S. FDA. We used these to evaluate efficacy, mortality, severe adverse events and suicidality. Results: The six pediatric studies enrolled 1,228 patients (828 drug/460 placebo). The seven adult drug approval programs enrolled 4,228 patients (2,356 drug/1,932 placebo). Mean mania rating scale baseline (pediatric=30.3/adult=30.3) scores were identical, and drug-placebo difference scores (pediatric=5.8/ adult=5.2) were not significantly different. There were no reported deaths during the pediatric trials. During the 23 adult trials there were 8 deaths (3 in drug group/5 in placebo group), a mortality rate of 3,290/100,000 patient exposure years. The proportion of patients that reported severe adverse events was slightly lower for the pediatric (4.2%) as compared to adult (4.7%) trials. A higher proportion of children (5/460, 1.1%) than adult (7/2,012, 0.3%) patients assigned to placebo reported suicidality, χ2(df=1)=4.2, p=0.04. We did not find evidence of increased suicidality for children assigned to drug (7/828, 0.8%) as compared to the children assigned to placebo (5/460, 1.1%).

Original languageEnglish (US)
Pages (from-to)122-127
Number of pages6
JournalIsrael Journal of Psychiatry and Related Sciences
Volume49
Issue number2
StatePublished - 2012

Fingerprint

Pediatrics
Safety
Placebos
Pharmaceutical Preparations
Bipolar Disorder
Drug Approval
Mortality
Suicide
Antidepressive Agents
Depression

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Efficacy and safety of anti-manic agents in children and adults. / Khan, Arif; Faucett, James; Emslie, Graham J.; Brown, Walter A.

In: Israel Journal of Psychiatry and Related Sciences, Vol. 49, No. 2, 2012, p. 122-127.

Research output: Contribution to journalArticle

Khan, Arif ; Faucett, James ; Emslie, Graham J. ; Brown, Walter A. / Efficacy and safety of anti-manic agents in children and adults. In: Israel Journal of Psychiatry and Related Sciences. 2012 ; Vol. 49, No. 2. pp. 122-127.
@article{025a5a019e964fcb9c529b64ca2ff543,
title = "Efficacy and safety of anti-manic agents in children and adults",
abstract = "Objective: Pediatric trials in depression have led to major concerns about potential suicide inducing properties of antidepressants and doubts about their efficacy. Several trials of anti-manic agents in children were recently conducted and regulatory reviews of the data have become available. Methods: We acquired pediatric and adult anti-mania agent Medical and Statistical Reports from the U.S. FDA. We used these to evaluate efficacy, mortality, severe adverse events and suicidality. Results: The six pediatric studies enrolled 1,228 patients (828 drug/460 placebo). The seven adult drug approval programs enrolled 4,228 patients (2,356 drug/1,932 placebo). Mean mania rating scale baseline (pediatric=30.3/adult=30.3) scores were identical, and drug-placebo difference scores (pediatric=5.8/ adult=5.2) were not significantly different. There were no reported deaths during the pediatric trials. During the 23 adult trials there were 8 deaths (3 in drug group/5 in placebo group), a mortality rate of 3,290/100,000 patient exposure years. The proportion of patients that reported severe adverse events was slightly lower for the pediatric (4.2{\%}) as compared to adult (4.7{\%}) trials. A higher proportion of children (5/460, 1.1{\%}) than adult (7/2,012, 0.3{\%}) patients assigned to placebo reported suicidality, χ2(df=1)=4.2, p=0.04. We did not find evidence of increased suicidality for children assigned to drug (7/828, 0.8{\%}) as compared to the children assigned to placebo (5/460, 1.1{\%}).",
author = "Arif Khan and James Faucett and Emslie, {Graham J.} and Brown, {Walter A.}",
year = "2012",
language = "English (US)",
volume = "49",
pages = "122--127",
journal = "Israel Journal of Psychiatry and Related Sciences",
issn = "0333-7308",
publisher = "Mediafarm Group",
number = "2",

}

TY - JOUR

T1 - Efficacy and safety of anti-manic agents in children and adults

AU - Khan, Arif

AU - Faucett, James

AU - Emslie, Graham J.

AU - Brown, Walter A.

PY - 2012

Y1 - 2012

N2 - Objective: Pediatric trials in depression have led to major concerns about potential suicide inducing properties of antidepressants and doubts about their efficacy. Several trials of anti-manic agents in children were recently conducted and regulatory reviews of the data have become available. Methods: We acquired pediatric and adult anti-mania agent Medical and Statistical Reports from the U.S. FDA. We used these to evaluate efficacy, mortality, severe adverse events and suicidality. Results: The six pediatric studies enrolled 1,228 patients (828 drug/460 placebo). The seven adult drug approval programs enrolled 4,228 patients (2,356 drug/1,932 placebo). Mean mania rating scale baseline (pediatric=30.3/adult=30.3) scores were identical, and drug-placebo difference scores (pediatric=5.8/ adult=5.2) were not significantly different. There were no reported deaths during the pediatric trials. During the 23 adult trials there were 8 deaths (3 in drug group/5 in placebo group), a mortality rate of 3,290/100,000 patient exposure years. The proportion of patients that reported severe adverse events was slightly lower for the pediatric (4.2%) as compared to adult (4.7%) trials. A higher proportion of children (5/460, 1.1%) than adult (7/2,012, 0.3%) patients assigned to placebo reported suicidality, χ2(df=1)=4.2, p=0.04. We did not find evidence of increased suicidality for children assigned to drug (7/828, 0.8%) as compared to the children assigned to placebo (5/460, 1.1%).

AB - Objective: Pediatric trials in depression have led to major concerns about potential suicide inducing properties of antidepressants and doubts about their efficacy. Several trials of anti-manic agents in children were recently conducted and regulatory reviews of the data have become available. Methods: We acquired pediatric and adult anti-mania agent Medical and Statistical Reports from the U.S. FDA. We used these to evaluate efficacy, mortality, severe adverse events and suicidality. Results: The six pediatric studies enrolled 1,228 patients (828 drug/460 placebo). The seven adult drug approval programs enrolled 4,228 patients (2,356 drug/1,932 placebo). Mean mania rating scale baseline (pediatric=30.3/adult=30.3) scores were identical, and drug-placebo difference scores (pediatric=5.8/ adult=5.2) were not significantly different. There were no reported deaths during the pediatric trials. During the 23 adult trials there were 8 deaths (3 in drug group/5 in placebo group), a mortality rate of 3,290/100,000 patient exposure years. The proportion of patients that reported severe adverse events was slightly lower for the pediatric (4.2%) as compared to adult (4.7%) trials. A higher proportion of children (5/460, 1.1%) than adult (7/2,012, 0.3%) patients assigned to placebo reported suicidality, χ2(df=1)=4.2, p=0.04. We did not find evidence of increased suicidality for children assigned to drug (7/828, 0.8%) as compared to the children assigned to placebo (5/460, 1.1%).

UR - http://www.scopus.com/inward/record.url?scp=84864489663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864489663&partnerID=8YFLogxK

M3 - Article

C2 - 22801291

AN - SCOPUS:84864489663

VL - 49

SP - 122

EP - 127

JO - Israel Journal of Psychiatry and Related Sciences

JF - Israel Journal of Psychiatry and Related Sciences

SN - 0333-7308

IS - 2

ER -